New Results from the National Health and Wellness Survey Show Patients at High Risk for Stroke Have Lower Quality of Life, More Hospitalizations
NEW YORK, November 7, 2011—Nearly 40% of diagnosed “high-risk” atrial fibrillation (AF) patients in the 5EU are not taking an anticoagulant to prevent stroke, according to new findings from the National Health and Wellness Survey (NHWS), conducted by Kantar Health and presented today at the 14th ISPOR (International Society for Pharmacoeconomic and Outcomes Research) European Congress in Madrid, Spain. AF is a major independent risk factor for stroke, particularly in older patients, and patients with AF have an approximately 5% annual risk for stroke.
“Across all risk groups in the 5EU, 45% of all diagnosed AF patients aren’t taking an anticoagulant to prevent stroke,” says Gina Isherwood, Ph.D., Regional Brand Director with Kantar Health. “Our research shows that the tendency to take medication to prevent stroke increases along with risk status. Still, a large number of patients considered ‘high risk’ (CHA2DS2-VASc≥2) aren’t taking an anticoagulant. Being at high risk for stroke has substantial burden for these patients, reducing their physical quality of life and increasing healthcare resource use.”
Kantar Health’s data show that high-risk AF patients have significantly lower physical quality of life compared with low-risk AF patients, and both high- and moderate-risk patients had significantly lower health utility scores compared with low-risk patients. In addition, high-risk patients reported significantly more visits to their healthcare provider and a greater number of hospitalizations in the past six months than low- or moderate-risk patients (CHA2DS2-VASc=0-1).
“The increased number of hospitalizations and physician visits suggests these AF patients place a substantial burden on the healthcare system across the 5EU,” Dr. Isherwood says. “An unmet need remains for enhanced treatment of AF patients, especially patients considered at high risk of stroke. Understanding individual needs and local guidelines is necessary to improve patients’ quality of life and reduce the burden on the healthcare system across the 5EU.”
About the National Health and Wellness Survey (NHWS)
The study’s results were drawn from the 2010 European NHWS, a sample of 57,805 adults in France, Germany, Italy, Spain and the UK. The NHWS is a nationally representative, self-administered survey conducted annually via the Internet; topics covered include the health status, attitudes, behaviors and outcomes among adults 18 or older.
Kantar Health conducts the NHWS annually in the US, Europe, Asia and Latin America. The survey is the largest self-reported database in the healthcare industry.
About Kantar Health (www.kantarhealth.com)
Kantar Health is a global, evidence-based decision support partner to the world’s leading pharmaceutical, biotech, device and diagnostic companies. Our 700+ staff act as catalysts, working closely with customers to drive distinctive decision-making that helps them prioritize product development and portfolios, differentiate their brands and ensure product profitability after launch. We are unique in that we bring together clinical, medical and methodological expertise, commercial/marketing know-how and proprietary data. It is this rare combination, together with our unparalleled stakeholder reach, that enables us to mobilize incisive, imaginative and timely ROI-driven solutions, empowering clients to deliver better healthcare options to their customers.
With offices in over 40 countries, we excel at solving technically or logistically challenging projects around the world and across the product lifecycle, combining on-the-ground know-how and global and national proprietary data to quickly identify value drivers. As part of WPP, we can also incorporate highly innovative thinking from outside the industry into our solutions.
For more information on Kantar Health, please contact Paula Paradise, Vice President of Global Marketing, at firstname.lastname@example.org or +1-484-442-1431.